-+ 0.00%
-+ 0.00%
-+ 0.00%

COYA THERAPEUTICS PROVIDES ENROLLMENT UPDATE OF THE INVESTIGATOR-INITIATED PHASE 1 STUDY OF LOW DOSE INTERLEUKIN-2 (LD IL-2) + CTLA4-IG FUSION PROTEIN IN PATIENTS WITH FRONTOTEMPORAL DEMENTIA (FTD)

Reuters·12/18/2024 13:15:00

Please log in to view news